Mestag
1 known investors
Mestag Therapeutics develops first-in-class antibody therapeutics targeting fibroblast immunology for patients with cancer and inflammatory diseases. Its pipeline includes MST-0312, a bispecific antibody aimed at solid tumors via tertiary lymphoid structures, and the M402 program of agonist antibodies for conditions such as rheumatoid arthritis, IBD, and lupus.
Investors · 1
In the news
Frequently asked questions
- What does Mestag do?
- Mestag Therapeutics develops first-in-class antibody therapeutics targeting fibroblast immunology for patients with cancer and inflammatory diseases. Its pipeline includes MST-0312, a bispecific antibody aimed at solid tumors via tertiary lymphoid structures, and the M402 program of agonist antibodies for conditions such as rheumatoid arthritis, IBD, and lupus.
- Who are Mestag's investors?
- Mestag's investors include SV Health Investors.